EMA Refused: Balaxur (memantine hydrochloride;donepezil hydrochloride) — Merz Pharmaceuticals GmbH

View source ↗

Summary

EMA decision to refuse Balaxur (memantine hydrochloride; donepezil hydrochloride) for Alzheimer’s disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Balaxur

Snippet

Status: Refused. Therapeutic area: Alzheimer Disease. MAH: Merz Pharmaceuticals GmbH. Decision date: 18/10/2012